| Trial ID: | L2268 |
| Source ID: | NCT01100125
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: sitagliptin|DRUG: insulin dose increase
|
| Outcome Measures: |
Primary: The change of HbA1C, 24weeks | Secondary: the number of patients in HbA1C <7% without hypoglycemia, 24 weeks|hypoglycemia(symptoms consistent with hypoglycemia and confirmed by plasma glucose < 72 mg/dL), 24 weeks|the change of C-peptide, 24 weeks|the change of body weight and waist circumference, 24 weeks|the change of insulin dose, 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Seoul National University Bundang Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
140
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-04
|
| Completion Date: |
2012-11
|
| Results First Posted: |
|
| Last Update Posted: |
2013-10-25
|
| Locations: |
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, 463-707, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01100125
|
